Dr. Philip McMillan,  John McMillan

Susan Langlois spent forty-five years inside the vaccine industry, and she wants that on the record before she says anything else. She started in 1972 at Connaught Laboratories, the Canadian house that helped bring insulin to the world, and she built her career on regulatory approvals, clinical trials, and the unglamorous quality checks that decide whether a biological product is safe enough to inject into a healthy person. Her proudest achievement is not a headline. It is the work she did to get a tuberculosis vaccine, BCG, approved as a treatment for bladder cancer, threading eleven months of data through two national regulators. This is not a woman who dislikes vaccines. This is a woman who helped make them.

Which is exactly why her questions land differently. When someone who developed vaccines, and who regulated them, starts asking whether the pandemic-era mRNA products were held to the standard she spent a career upholding, the reflex to dismiss her as a crank runs into a wall of credentials. She says she is trying to save the industry, and the point is worth sitting with. Her worry is that a handful of companies took shortcuts that will poison public trust in every honest firm still doing the slow, careful work.

The Date That Changed the Rules

It all turns on a date most people have never heard of: 2013. That year, regulators clarified that an mRNA product designed to trigger an immune response would be regulated as a vaccine, not as a genetic therapy. It sounds like paperwork. It was anything but. Genetic products must clear extra hurdles that vaccines do not: tests for whether they cause or accelerate cancer, studies of where the product travels in the body (absorption, distribution, metabolism, excretion), and long-term follow-up of the patients who receive them. Reclassify the same technology as a vaccine, and those studies drop out of the requirements. Langlois reflected on the 2013 decision and felt her old regulatory instincts prickle. Why, she wondered, would anyone move a genetic technology out of the genetic rulebook years before there was a pandemic to use it for?

A Dose No One Can Measure

The second problem is one of dose, and it is more unsettling than it first appears. A traditional vaccine delivers a measured quantity of antigen. Every vial is tested, batch to batch, so that the shot a person receives in Toronto matches the shot given in Geneva. The body meets a fixed target, attacks it, and clears it. An mRNA vaccine does not work that way. It delivers instructions and asks the recipient’s own cells to manufacture the spike protein. How much protein? For how long? Nobody can say, because it depends on the person. Some make very little. Some make far too much. And a regulator cannot test the potency of a dose the body itself produces after the needle leaves the arm. The quality control that Langlois spent decades enforcing simply has no place to stand.

The Shortcuts Were in the Rulebook

Then came the phrase that still makes her bristle: no shortcuts. Officials repeated it like a mantra. The companies followed the regulations, they said, and took no shortcuts. Langlois does not accuse them of lying, and that is what makes her account so damning.

“They didn’t take any shortcuts because they followed the regulations,” she said. “But the regulations themselves had shortcuts.”

Exemptions were already baked into the rulebook before anyone rolled up a sleeve. Emergency-use provisions released the manufacturers from three ordinary obligations at once: the duty to recall a faulty product, the duty to obtain informed consent, and any legal liability for harm. Regulators reviewed roughly three months of clinical data, then crossed the placebo group over and gave those participants the vaccine too, erasing the comparison that would have let anyone measure long-term harm. And when the signal for myocarditis, inflammation of the heart muscle, grew impossible to ignore, it took five years to force that warning onto the label. Five years is a long time for a heart.

The most far-reaching worry Langlois raises is the one she calls grandfathering. Once a platform is accepted as safe, every new product built on it inherits that blessing. Swap in a different protein and, in her words, you are off to the races. Flu vaccines are already moving to mRNA. Lyme disease candidates are in development. None of them, she fears, will be asked to repeat the studies that were skipped the first time, because the regulators are now convinced the platform is safe by definition. A proper placebo-controlled safety trial will probably never be run, because running one would mean admitting the original products should have been recalled, and the whole edifice of public health would crack. So the proof that could settle the argument, in either direction, is the one proof no one has any incentive to gather.

It would be easy to cast Langlois as a pure skeptic, but she refuses the role. She is genuinely enthusiastic about mRNA for cancer, where injecting instructions to attack a solid tumor makes biological sense. She recognizes the real advantage of a platform that can be retargeted in weeks rather than years. Her objection is narrower and harder to wave away: a technology that scatters through the body does not belong in a healthy person’s arm until someone has done the distribution and cancer-risk work. Send it back to the genetic rulebook, she argues, do the studies, and then come back.

The Human Cost

When Langlois helped set up vaccination clinics in her Ontario town, she asked to see the consent form and was told there would be none; the exemption had removed it. She asked for the information brochure that named the groups who should not receive the shot (pregnant women, nursing mothers, people with autoimmune conditions) and was told the government had never supplied it. Those original brochures, she says, later disappeared from the internet. She lost family members during those years. She was told she should not be allowed into an emergency ward because she was unvaccinated. And through all of it she kept diaries, five or more of them, handwritten, so that no one could later tell her she had misremembered.

Her rule for making sense of any of it is blunt: follow the money. Since regulators began charging pharmaceutical companies for the reviews and inspections that fund their own operations, she asks, how could that relationship stay independent? She does not claim to have proof of collusion. She claims only to have watched, and written it down.

What does rebuilding look like? Not, she insists, pretending the problems were imagined. Dr. Philip McMillan, a British clinician and researcher who interviewed her, put forward an image that is hard to shake.

“Trust is like glass,” he said. “Once you break it, you can’t stick it back together.”

The path Langlois describes is unglamorous and slow. Companies should develop new products properly. Governments should reopen the regulations that were quietly changed and run honest risk-benefit reviews of what is already on the market. That is a tall order, and she is not sure it will happen. But the alternative, insisting nothing went wrong while trust drains away, is the one outcome she is certain the industry cannot survive.